Request Your Free Infographic Now:

"Rapid-Turnaround Oncomine Precision Assay Enables Global Harmonization for Clinical Trial Testing"

Genetic variation in neoplasia can take the form of single or multiple nucleotide variants, gene fusions, amplifications, and/or splice variations. This heterogeneity can pose a challenge in comprehensive profiling to guide therapeutic decision making.

The Oncomine Precision Assay on the Genexus Integrated Sequencer is an amplicon-based automated NGS assay that enables the detection of all these genomic variant classes, spanning 50 genes, focused on those with the greatest clinical relevance and targets of many ongoing trials. The complete workflow, from library prep to final report generation, can be accomplished in less than 30 hours for up to 32 formalin-fixed paraffin-embedded samples. OPAGX uses AmpliSeq HD technology, utilizing unique molecular tags for sequencing error correction and increased sensitivity of variant detection.

This poster from Q2 Solutions describes a study in which the Oncomine Precision Assay on the Genexus Integrated Sequencer was characterized at a Durham, NC-based site and then transferred to and validated by a genomics laboratory in Beijing, enabling global harmonization of clinical trial testing.

Offered Free by: Q2 Solutions
See All Resources from: Q2 Solutions